We are live on ! Find out more
PRAH

PRA Health Sciences, Inc.
PRAH

Delisted

PRAH was delisted on the 30th of June, 2021.

189 hedge funds and large institutions have $3.37B invested in PRA Health Sciences, Inc. in 2016 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 84 increasing their positions, 58 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 19

45% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 58

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

9% more funds holding

Funds holding: 173189 (+16)

3% less capital invested

Capital invested by funds: $3.48B → $3.37B (-$111M)

67% less call options, than puts

Call options by funds: $430K | Put options by funds: $1.31M

Holders
189
Holders Change
+16
Holders Change %
+9.25%
% of All Funds
4.72%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
36
Increased
84
Reduced
58
Closed
19
Calls
$430K
Puts
$1.31M
Net Calls
-$883K
Net Calls Change
-$1.63M
Name Holding Trade Value Shares
Change
Change in
Stake
CG
126
Clinton Group
New York
$787K +$784K +14,286 New
CIC
127
Chase Investment Counsel
Virginia
$779K +$234K +4,255 +43%
AIG
128
American International Group
New York
$767K -$2.03K -37 -0.3%
CCMH
129
Cornerstone Capital Management Holdings
New York
$765K +$763K +13,900 New
PP
130
Paloma Partners
Connecticut
$763K +$107K +1,942 +16%
UBS AM
131
UBS AM
Illinois
$703K -$268K -4,885 -28%
CIC
132
Cornercap Investment Counsel
Georgia
$681K +$25.8K +470 +4%
RJA
133
Raymond James & Associates
Florida
$654K +$128K +2,325 +24%
Walleye Trading
134
Walleye Trading
New York
$639K +$636K +11,593 New
1GA
135
1st Global Advisors
Texas
$608K +$8.29K +151 +1%
BBP
136
Banco BTG Pactual
Brazil
$606K +$604K +11,000 New
BC
137
Brinker Capital
Pennsylvania
$596K +$593K +10,809 New
SGA
138
Strategic Global Advisors
California
$589K -$187K -3,404 -24%
SB
139
Suntrust Banks
Georgia
$587K -$3.51K -64 -0.6%
AG
140
Algert Global
California
$547K +$545K +9,927 New
VOYA Investment Management
141
VOYA Investment Management
Georgia
$533K
Legal & General Group
142
Legal & General Group
United Kingdom
$511K +$154K +2,803 +43%
Capstone Investment Advisors
143
Capstone Investment Advisors
New York
$496K +$494K +9,000 New
TI
144
Trexquant Investment
Connecticut
$485K +$483K +8,800 New
D.E. Shaw & Co
145
D.E. Shaw & Co
New York
$482K -$276K -5,029 -36%
AL
146
Airain Ltd
Guernsey
$469K +$467K +8,514 New
Fisher Asset Management
147
Fisher Asset Management
Washington
$445K +$443K +8,075 New
AP
148
AHL Partners
United Kingdom
$434K -$245K -4,473 -36%
OAM
149
Oxford Asset Management
United Kingdom
$432K +$430K +7,830 New
Fuller & Thaler Asset Management
150
Fuller & Thaler Asset Management
California
$424K +$302K +5,500 +250%

PRAH Hedge Fund Activity: Q4 2016 in Review

189 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in PRA Health Sciences, Inc. (PRAH) for Q4 2016, worth a combined $3.37B — down 3.2% from $3.48B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PRAH positions and 19 closed out — a net gain of 17 holders — while 84 added to existing stakes and 58 trimmed.

The largest buyer was Vanguard Group, adding an estimated $46.4M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $412M.

  • 189 institutional investors held PRA Health Sciences, Inc. (PRAH) as of Q4 2016, up from 173 in Q3 2016.
  • Funds reported $3.37B of PRA Health Sciences, Inc. stock for Q4 2016, down 3.2% quarter-over-quarter.
  • 36 funds opened new PRA Health Sciences, Inc. positions in Q4 2016 and 19 closed out, a net change of +17 holders.
  • The largest PRA Health Sciences, Inc. buyer in Q4 2016 was Vanguard Group, an estimated $46.4M added.
  • The largest PRA Health Sciences, Inc. seller in Q4 2016 was Kohlberg Kravis Roberts & Co, an estimated $412M sold.

Based on aggregated 13F filings for Q4 2016.